Introduction
============

Melanoma is the most lethal skin malignancy, and the estimated number of new cases with melanoma of the skin based on conventional cancer incidence rates is 96,480 and the estimated number of cases of mortality is 7,230 for 2019 ([@b1-ol-0-0-10284]--[@b3-ol-0-0-10284]). Cutaneous melanoma is the fifth most common type of cancer, with its incidence rate increasing continuously during the past decades ([@b4-ol-0-0-10284],[@b5-ol-0-0-10284]). Despite high diagnostic accuracy and appropriate treatment due to medical advances, its pathogenesis and natural course remain unclear.

Melanoma is a malignant type of tumor, which may be composed of epidermal melanocytes, nevocytes or dermal melanocytes. Epidemiology studies revealed that melanoma is likely to be caused by hereditary factors and environmental risk factors, including sex, age, ethnicity and geographic location ([@b6-ol-0-0-10284],[@b7-ol-0-0-10284]). This is in line with the most vital and potentially reversible risk factor of malignant melanoma arising from an interaction between environmental exposure and genetic susceptibility. Gandini *et al* ([@b8-ol-0-0-10284]) revealed the association between melanoma and ultraviolet (UV)-irradiation, and concluded that intermittent sunlight may be a vital determinant of risk. Additionally, other types of UV ray exposure, including sunburn and artificial UV-irradiation, may cause melanoma development ([@b9-ol-0-0-10284],[@b10-ol-0-0-10284]). Out of all melanoma cases, \~25% occur together with pre-existing moles, suggesting that melanocytes are benign accumulations of themselves and nevus cells ([@b11-ol-0-0-10284]). A family history may be a strong risk factor for the disease, and provides a direction for elucidating the genetic basis of melanoma ([@b12-ol-0-0-10284],[@b13-ol-0-0-10284]). In addition, melanoma has a high degree of malignancy, and is prone to early lymphoid and blood tract metastasis, which are associated with poor prognosis; therefore, it is important to identify susceptibility genes. Genomic profiling and sequencing will form the basis for molecular taxonomy for more accurate subgrouping of patients with melanoma in the future.

Identification of associated genes is a central challenge of modern genetics aiming to modulate signal pathways and biological processes for a number of well-known diseases, including various types of cancer. Melanoma is highly complicated; therefore, research strategies are limited. Computational methods provide important complementary tools for this problem. Over the past decades, as biotechnology has advanced, a large amount of gene expression data has been collected and submitted to several large-scale databases. These have been extensively used to explore the molecular mechanism of tumorigenesis with bioinformatics analysis methods ([@b14-ol-0-0-10284],[@b15-ol-0-0-10284]). However, a previous study ([@b16-ol-0-0-10284]) based on sequence- and network-based methods has been conducted to identify melanoma-associated genes.

The purpose of the present study was to establish a comprehensive method to identify melanoma-associated biological mechanisms and to predict key genes associated with melanoma using the random walk method. Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were analyzed to illuminate the biological pathways and processes which may be altered in patients with melanoma. Additionally, network and Kaplan-Meier analyses identified several potential therapeutic targets for melanoma. The results of the present study may provide novel strategies for diagnosis and treatment of melanoma and uncover the probable mechanism of tumorigenesis.

Materials and methods
=====================

### Data collection/data set

The present study searched for genes associated with melanoma using the Online Mendelian Inheritance in Man (OMIM) database (<https://www.omim.org/>), which is a comprehensive, authoritative and timely research resource, and includes descriptions of human genes, phenotypes and their associations ([@b17-ol-0-0-10284]). A total of 74 melanoma-associated genes were identified. These were used as seed genes for prioritization of melanoma candidate genes in the present study.

The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (<http://string-db.org>) provides a comprehensive catalogue of protein-protein interactions along with their confidence score according to means obtaining them. In the present study, the full list of gene pairs as background was obtained and the melanoma-associated network was extracted by retaining only the direct neighborhoods of the 74 seed genes, which resulted in a network of 11,181 genes and 39,043 interaction pairs.

### Prioritization of melanoma candidate genes

Random walk on heterogeneous networks is an emerging approach for effective disease gene prioritization. Melanoma-associated genes obtained from OMIM and candidate genes in the melanoma-associated network were used as inputs. The random walk algorithm produced a ranked list of the genes, according to their strength of association with melanoma. The risk score of each candidate gene was calculated as follows:
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Where pt represents the melanoma risk vector at walk step *t*, the parameter *r* ϵ (0, 1) is the restart probability, and *Q* is the risk probability transfer matrix.

According to the Perron-Frobenius theorem ([@b18-ol-0-0-10284]), the eigenvalues of stochastic matrix *Q* are in the range of \[-1, 1\] and *r*=0.1 was finally obtained as the optimal parameter. Generally, the transition probability from gene *qi* to phenotype *qj* is defined as:

q

i

j

=

w

i

j

∑

k

∈

n

e

i

g

h

b

o

r

(

i

)

w

k

j

![](ol-18-01-0127-g01.jpg)

These probabilities can reach a steady state following a sufficiently large number of iterations. The iterations were conducted until the difference between *p*^s^ and *p*^s+1^ (measured by the L^1^ norm) fell below 10^−6^.

### Functional enrichment analysis

The GO database (<http://geneontology.org>), which unifies genetic and gene product characteristics of all species, is an effective and efficient tool to screen genes. In the present study, GO functional enrichment analysis of melanoma candidate genes was performed to interpret their biological significance using the WEB-based Gene SeT AnaLysis Toolkit (<http://www.webgestalt.org>) ([@b19-ol-0-0-10284]), with a cut-off criterion of P\<0.05.

The full list of KEGG pathways was downloaded from the KEGG database (<https://www.genome.jp/kegg/>), and pathway enrichment analysis for melanoma candidate genes was conducted using the following formula:
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Where N is the total number of genes in the KEGG pathway database, n is the number of melanoma candidate genes annotated by the KEGG pathway database, m is the number of melanoma candidate genes annotated by a specific KEGG pathway and M is the total number of genes involved in a specific pathway. KEGG pathways were considered as statistically significant if P\<0.05 following correction using the Benjamini-Hochberg method ([@b20-ol-0-0-10284]).

### Pathway crosstalk analysis

Associations among significantly enriched pathways were explored through crosstalk analysis using the overlap coefficient (OC) and the Jaccard coefficient (JC), which were defined as follows:
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Where A and B represent the melanoma candidate gene numbers contained in pathway A and pathway B, respectively. Pathway A and pathway B were considered to be connected if OC\>0.5 and JC\>0.25. Furthermore, Cytoscape 3.0 software (<http://cytoscape.org/>) was used to visualize connections among KEGG pathways.

### Melanoma-specific network analysis

The melanoma candidate genes were uploaded to the STRING database to obtain a melanoma-specific network by using the threshold of confidence score \>0.4. Additionally, gene degree and betweenness were applied for evaluating gene importance in the network. Khuri and Wuchty ([@b21-ol-0-0-10284]) hypothesized that MDSets could provide a novel method of evaluating the core proteins of an organism. The present study considered genes contained in the MDSet with a high degree and betweenness as important biomarkers for melanoma progression.

### Survival analysis

To evaluate the association among melanoma-associated biomarkers and survival rates, the Gene Expression Profiling Interactive Analysis (GEPIA; <http://gepia.cancer-pku.cn>) database was used to perform survival analysis. Melanoma samples were classified into high or low expression groups according to the median expression value of specific respective genes. The Kaplan-Meier method and a two-side log-rank test were used for overall survival comparison between two groups. P\<0.05 was considered to indicate a statistically significant difference.

### Statistical analysis

All statistical analyses were conducted in R version 3.4.1 (<https://www.r-project.org/>). For functional analysis, the enrichment method was used. For survival analysis, the Kaplan-Meier method was adopted to plot survival curves, followed by a log-rank test to compare the differences between the survival curves. Data was presented as the mean ± standard deviation with at least three repeats in every group. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Melanoma candidate gene prioritization

[Fig. 1](#f1-ol-0-0-10284){ref-type="fig"} shows the workflow of the present study. A total of 74 genes were reported to be associated with melanoma in the OMIM database, and used as seed genes for following analyses. Additionally, 39,043 interaction pairs among 11,181 genes were obtained from the STRING database by extracting the direct interactions of the 74 seed genes, which was considered as the melanoma-associated network. By applying the random walk algorithm to the 74 seed genes and 11,181 candidate genes, a score was assigned to every candidate gene and the top 1% of genes (n=111) with the highest scores were considered as melanoma-associated genes.

### Significantly enriched functions

The 111 melanoma-associated genes were identified to be significantly enriched in 13 GO biological process (BP) terms, two cellular component (CC) terms and two molecular function terms ([Fig. 2A](#f2-ol-0-0-10284){ref-type="fig"}). The BP terms mainly involved in the process of pigmentation, catabolism, telomeres and thymus development. The CC terms melanosome and pigment granule were also considerably enriched. These are involved in pigmentation.

Enrichment Map (<http://www.baderlab.org/Software/EnrichmentMap>) was used to explore the associations among significantly enriched GO terms, which resulted in two clusters ([Fig. 2B](#f2-ol-0-0-10284){ref-type="fig"}). One cluster included biological processes associated with telomeres and pigmentation, including 'telomere maintenance' and 'pigment cell differentiation', and the other cluster included biological processes associated with catabolism.

There were 30 pathways that were significantly enriched in association with the 111 melanoma-associated genes ([Table I](#tI-ol-0-0-10284){ref-type="table"}), and 12 of them were involved in cancer-associated processes. In addition, endocrine system pathways (melanogenesis and gonadotropin-releasing hormone signaling pathway) and pathways in the translation process \[epidermal growth factor receptor signaling pathway and mechanistic target of rapamycin (mTOR) signaling pathway\] were also included in the results. The immune system (T cell receptor signaling pathway, NOD-like receptor signaling pathway and natural killer cell mediated cytotoxicity) was identified to be overrepresented in melanoma-associated genes. Pathway crosstalk analysis obtained two pathway clusters that were associated with cancer development and the neuroendocrine system, respectively, which were connected by pathways in cancer ([Fig. 2C](#f2-ol-0-0-10284){ref-type="fig"}).

### Melanoma-specific network

[Fig. 3A](#f3-ol-0-0-10284){ref-type="fig"} illustrates the melanoma-specific network that contains 56 melanoma-associated genes and 98 gene pairs. The network MDSet, obtained by using the binary integer linear method, contained 16 genes. Three genes, including tyrosinase (TYR), mitogen-activated protein kinase (MAPK) 3 and cancer/testis antigen 2 (CTAG2), intersected with the top 16 genes with highest betweenness or degree and were considered as important melanoma progression biomarkers. [Fig. 3B](#f3-ol-0-0-10284){ref-type="fig"} illustrates associations of genes in the network with significantly enriched GO terms and KEGG pathways.

### Survival analysis

Associations among genes contained in the network and overall survival rates of patients with melanoma were evaluated using the GEPIA database. As a result, two genes contained in the MDSet, hedgehog acyltransferase (HHAT) and BRCA1-associated protein 1 (BAP1), and another two genes, TYR and microphthalmia-associated transcription factor (MITF), were identified to be significantly associated with the overall survival rates of patients with melanoma. Elevated expression levels of the four genes were all closely associated with poor melanoma prognosis ([Fig. 4](#f4-ol-0-0-10284){ref-type="fig"}).

Discussion
==========

The purpose of the present study was to explore the underlying mechanism of melanoma and potential gene biomarkers using comprehensive bioinformatics methods. The random walk method identified 111 potential melanoma-associated genes, and functional enrichment analysis identified several biological processes and pathways which may contribute to melanoma progression. A melanoma-specific network in combination with survival analysis identified more reliable biomarkers for melanoma diagnosis and treatment.

GO enrichment analysis indicated that 'developmental pigmentation', 'pigmentation' and 'pigment cell differentiation' were closely associated with melanoma-associated genes. Pigmentation is determined by the proportion of several melanin species, for instance the alkali soluble yellow-red pheomelanin and insoluble brown-black eumelanin ([@b22-ol-0-0-10284]). Synthesis of the two types of melanin starts with the tyrosine oxidation of TYR, which produces L-3,4-dihydroxyphenylalanine, which then produces dopaquinone and eventually the common precursor. The range of individual pigmentation phenotypes is the result of the ratio of true melanin to brown melanin. Individuals with darker hair or skin possess higher ratios of true melanin to brown melanin than those with lighter hair or skin. Several studies have demonstrated that skin which contains brown melanin provides weak UV protection, suggesting that brown melanin may actually be a prooxidant and photosensitive to DNA damage, while eumelanin may act as a light-protective antioxidant ([@b23-ol-0-0-10284],[@b24-ol-0-0-10284]). Reactive oxygen species (ROS) may also be produced as byproducts during pigment synthesis ([@b24-ol-0-0-10284]). It has been considered that the role of melanocyte organelles is to provide protection against ROS-induced injury by containment ([@b25-ol-0-0-10284]). Leakage of toxic substances from the melanosome can be damaging to melanocytes. Additionally, pheomelanin synthesis stimulates melanoma genesis via an UV-independent pathway that induces ROS-mediated DNA damage, which may lead to melanoma carcinogenesis ([@b26-ol-0-0-10284]).

The deubiquitinating enzyme BAP1 is a tumor suppressor, which is inactivated in a variety of types of cancer ([@b27-ol-0-0-10284]). BAP1 inactivation is expected to affect transcription regulation, either through direct gene expression dysregulation or chromatin structure perturbation ([@b28-ol-0-0-10284],[@b29-ol-0-0-10284]). It has been reported that BAP1 affects ROS homeostasis and serves a major role in regulating cell morphology, cell migration and mitochondrial respiration in mesothelioma ([@b30-ol-0-0-10284]). In uveal melanoma, BAP1 inactivation is associated with metastasis development and poor prognosis ([@b31-ol-0-0-10284]). Therefore, BAP1 may promote tumor cell motility and invasiveness, and stimulates metastasis formation *in vivo*, which is consistent with the results of the study by Joseph *et al* ([@b32-ol-0-0-10284]).

MITF is the main regulator of melanocytes and serves a vital role in the pigmentation pathway. It also has antioxidant and prooxidant components ([@b33-ol-0-0-10284]). There are at least nine isoforms of MITF, which exhibit tissue-specific expression patterns, and the M isoform of MITF is selectively expressed in melanocytes ([@b34-ol-0-0-10284]). Melanoma is considered to arise from melanocytes, the pigment-producing cells of the skin, hair and eyes. In addition to its vital roles in normal melanocytes, MITF may also serve vital roles in melanoma, where it has been revealed to be a genetically-specific survival oncogene that is amplified in \~20% of human types of melanoma ([@b35-ol-0-0-10284]). Previously, MITF has been demonstrated to be involved in regulating metabolism and oxidative stress by directly regulating the expression of the main mitochondrial regulator; peroxisome proliferator-activated receptor γ coactivator 1 α ([@b36-ol-0-0-10284]).

The TYR gene, which encodes melanogenesis enzymes, has been associated with melanoma ([@b37-ol-0-0-10284]). Subsequent to identifying that variants of TYR affect pigmentation features, these same variants were revealed to be associated with the risk of skin cancer, even when accounting for available assessments of pigmentation ([@b38-ol-0-0-10284]). The association of TYR and its variants is robust in regulating pigmentation effects.

The hedgehog family of secreted proteins act as morphogens to control embryonic patterning and development in a variety of organ systems. HHAT mutation occurs in the conserved membrane bound O-acyltransferase domain. HHAT has been demonstrated to be expressed in the somatic cells of XX and XY gonads at the time of sex determination, and HHAT loss of function recapitulates the majority of the testicular, skeletal, neuronal and growth defects observed in humans ([@b39-ol-0-0-10284]). In the developing testis, HHAT is not required for Sertoli cell commitment but serves a role in proper testis cord formation and the differentiation of fetal Leydig cells.

Optimal BP terms were consistent with expectations, and several catabolism-associated terms were among them. Optimal features contained the terms ganglioside catabolic process, oligosaccharide catabolic process, glycosphingolipid catabolic process, ceramide catabolic process, transfer RNA threonylcarbamoyladenosine metabolic process and glycolipid catabolic process. A previous study demonstrated that numerous melanoma genes control cell metabolism, suggesting that melanoma may be a metabolic disease ([@b40-ol-0-0-10284]). Melanoma patterns in normal cells depend on the availability of substrates and oxygen. The regulation of metabolic pathways in cancer cells and the regulation of metabolic pathways in normal cells are significantly different. A number of studies have revealed fundamental differences in metabolic characteristics between normal melanocytes and melanoma cells *in vitro* ([@b41-ol-0-0-10284]--[@b43-ol-0-0-10284]). The metabolic characteristics of the two cell types were further characterized by the use of stable isotopes as tracers to quantify cell metabolic flux ([@b44-ol-0-0-10284]). According to the Warburg effect, the relative contribution of mitochondrial respiration to energy production in melanoma cells is generally low due to its higher glycolytic rate. In addition, melanoma cells exhibit high levels of glutaminase, which is the reverse flux of the tricarboxylic acid cycle and provides carbon for synthesis of fatty acids ([@b44-ol-0-0-10284]).

A total of 40--60% of cutaneous types of melanoma harbor B-Raf proto-oncogene (*BRAF*)^V600^ mutations ([@b45-ol-0-0-10284]). *BRAF* mutations are known to constitutively activate the MAPK signaling pathway ([@b46-ol-0-0-10284],[@b47-ol-0-0-10284]). MAPK3 belongs to the MAPK family, which includes extracellular signal regulation kinases ([@b48-ol-0-0-10284]). When activated by upstream kinases, MAPK phosphorylates several transcription factors and serves a vital role in regulating cancer cell proliferation, differentiation and other cellular activities directly associated with cancer. A previous study revealed that the expression levels of members of the MAPK signaling pathway were altered in patients with metastatic melanoma, which may activate this signaling pathway ([@b49-ol-0-0-10284]).

The telomere-associated terms, including 'telomere maintenance', 'telomere organization' and 'establishment of protein localization to telomere', may also be associated with melanoma. Telomere length was considered to be a major risk factor for melanoma, increasing melanoma risk in a study of 557 cases ([@b50-ol-0-0-10284]), and increasing nevus number ([@b51-ol-0-0-10284],[@b52-ol-0-0-10284]). In addition, high penetrative melanoma mutations were reported in genes encoding the protection of telomeres 1 (POT1) components, which are essential for telomere maintenance and signal transduction functions ([@b53-ol-0-0-10284]). POT1 mutations result in longer telomeres ([@b54-ol-0-0-10284]). A previous study investigated the mechanism of melanoma, and hypothesized that longer telomeres increase the duration of cell proliferation in a melanocytic nevus ([@b52-ol-0-0-10284]). If the process of aging is delayed in melanocytes, it could lead to further mutations, which increases the probability of developing a malignant tumor ([@b50-ol-0-0-10284]).

The thymus development process is also associated with melanoma. Interleukin-32 (IL-32) is a novel cytokine, involved in cancer development, and expressed in numerous human tissues and organs, including the thymus. Nicholl *et al* ([@b55-ol-0-0-10284]) reported that exogenous addition of IL-32 can effectively inhibit the proliferation of human melanoma cell lines, and that it is associated with increased expression of p21, p53 and tumor necrosis factor receptor superfamily member 10a. In previous studies, IL-32 has been reported to inhibit the growth and metastasis of cancer cells by regulating nuclear factor κB (NF-κB) signaling ([@b56-ol-0-0-10284],[@b57-ol-0-0-10284]). NF-κB is a transcription factor that regulates the expression of cytokines, growth factors and apoptosis inhibiting factors. Additionally, IL-32 is associated with signal transducer and activator of transcription 3 (STAT3) signaling in cancer cell growth ([@b58-ol-0-0-10284]). Numerous studies have reported that STAT3 signaling promotes cancer development, while loss of STAT3 inhibits cancer development ([@b59-ol-0-0-10284]--[@b61-ol-0-0-10284]).

In KEGG pathway analysis, certain types of cancer, including pancreatic and bladder cancer, were significantly enriched, which may indicate that melanoma has a similar phenotype, mechanism or co-morbidity with these types of cancer. Pathways, including chronic myeloid leukemia and acute myeloid leukemia, are directly associated with cancer and potential oncogenes. As a result, the abnormal expression of oncogenes may lead to cell cycle disturbances, continued cell proliferation, reduced apoptosis and tumor metastasis ([@b62-ol-0-0-10284]). The mTOR signaling pathway is involved in regulating cell growth, division, survival and transcription ([@b63-ol-0-0-10284]). Overactivation of mTOR can promote proliferation and reduce apoptosis. In addition, mTOR pathway dysfunction has been observed in several types of tumor ([@b64-ol-0-0-10284],[@b65-ol-0-0-10284]). A previous study suggested that CTAG2 is closely associated with cancer/testis antigen 1B (CTAG1B) ([@b66-ol-0-0-10284]). CTAG2 and CTAG1B are overexpressed in numerous types of tumor, including melanoma, sarcoma and multiple myeloma, as well as certain types of carcinoma, including lung, head and neck, and ovarian carcinoma ([@b66-ol-0-0-10284],[@b67-ol-0-0-10284]).

In the present study, TYR, HHAT, BAP1 and MITF were identified as potential therapeutic targets for melanoma. As the occurrence and development of melanoma is a complex event, the specific roles of these genes in the regulatory network remain to be determined by further experiments. Furthermore, in addition to the present study, multiple biomarkers have been identified to be associated with melanoma progression, proliferation, immune response, oncogenesis and other aspects by microarray studies ([@b68-ol-0-0-10284],[@b69-ol-0-0-10284]). As the public databases used, including OMIM and STRING, did not provide patient characteristics information, the association between the expression levels of candidate genes and clinicopathological parameters could not be assessed. Further analysis will be conducted in a future study with information from The Cancer Genome Atlas and Gene Expression Omnibus data sets. Additionally, it remains a great challenge to apply this information in a therapeutic manner.

In conclusion, in the present study, prioritization and comprehensive analysis of melanoma candidate genes were conducted to obtain several potential biomarkers and biological processes which may contribute to melanoma progression. This should be helpful in understanding the underlying mechanisms of melanoma, as well as for its diagnosis and treatment. However, further experimental validation of the results of the present study is required.
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![Schematic explaining the workflow of the present study. OMIM, Online Mendelian Inheritance in Man; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins.](ol-18-01-0127-g05){#f1-ol-0-0-10284}

![Significantly enriched GO terms and KEGG pathways of 111 melanoma-associated genes. (A) Dot plot illustrating the full list of significantly enriched GO terms and their corresponding logarithm transformed P-values and gene numbers. (B) GO term clustering analysis according to overlapping genes among them. (C) KEGG pathway crosstalk analysis. Nodes represent pathways, and two nodes are connected if there are any overlapping genes between them. Larger node size indicates more genes contained in a pathway, and thicker edges indicate more overlapping genes between two pathways. BP, biological process; CC, cellular component; GnRH, gonadotropin-releasing hormone; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function.](ol-18-01-0127-g06){#f2-ol-0-0-10284}

![Melanoma-specific network analysis. (A) Melanoma-specific network. (B) Allocation of genes contained in the network to significantly enriched GO terms and Kyoto Encyclopedia of Genes and Genomes pathways. Function was defined according to GO terms. GO, Gene Ontology.](ol-18-01-0127-g07){#f3-ol-0-0-10284}

![Kaplan-Meier curves for melanoma samples with lower (blue lines) or higher (red lines) expression levels of TYR, HHAT, BAP1 and MITF. The median expression values were used as thresholds. n=228 for HHAT as the data for one case was not available. BAP1, BRAC1 associated protein 1; HHAT, hedgehog acyltransferase; HR, hazard ratio; MITF, melanocyte inducing transcription factor; TYR, tyrosinase.](ol-18-01-0127-g08){#f4-ol-0-0-10284}

###### 

Significantly enriched Kyoto Encyclopedia of Genes and Genomes pathways of the 111 melanoma-associated genes.

  Pathway                                     P-value       PBH-value     Melanoma-associated genes included in the pathway
  ------------------------------------------- ------------- ------------- -------------------------------------------------------------------
  Melanoma                                    9.45×10^−7^   1.30×10^−4^   MITF; CDK4; BRAF; MAPK3; MAPK1; CDKN2A
  Bladder cancer                              1.32×10^−6^   1.30×10^−4^   CDK4; BRAF; MAPK3; MAPK1; CDKN2A
  Pancreatic cancer                           6.10×10^−7^   1.30×10^−4^   CDK4; BRCA2; BRAF; MAPK3; MAPK1; CDKN2A
  Non-small cell lung cancer                  6.37×10^−6^   4.21×10^−4^   CDK4; BRAF; MAPK3; MAPK1; CDKN2A
  Melanogenesis                               7.12×10^−6^   4.21×10^−4^   GNAQ; MITF; TYR; MC1R; MAPK3; MAPK1
  Long-term depression                        8.99×10^−6^   4.43×10^−4^   GNAQ; GNA11; BRAF; MAPK3; MAPK1
  Glioma                                      1.34×10^−5^   4.94×10^−4^   CDK4; BRAF; MAPK3; MAPK1; CDKN2A
  Pathways in cancer                          1.18×10^−5^   4.94×10^−4^   GNAQ; MITF; CDK4; BRCA2; GNA11; BIRC7; BRAF; MAPK3; MAPK1; CDKN2A
  Chronic myeloid leukemia                    2.36×10^−5^   7.77×10^−4^   CDK4; BRAF; MAPK3; MAPK1; CDKN2A
  Other glycan degradation                    8.13×10^−5^   2.41×10^−3^   NEU4; NEU2; NEU3
  Vascular smooth muscle contraction          2.55×10^−4^   6.67×10^−3^   GNAQ; GNA11; BRAF; MAPK3; MAPK1
  Long-term potentiation                      2.70×10^−4^   6.67×10^−3^   GNAQ; BRAF; MAPK3; MAPK1
  Thyroid cancer                              3.51×10^−4^   7.99×10^−3^   BRAF; MAPK3; MAPK1
  Gap junction                                8.11×10^−4^   1.60×10^−2^   GNAQ; GNA11; MAPK3; MAPK1
  ErbB signaling pathway                      7.77×10^−4^   1.60×10^−2^   NCK1; BRAF; MAPK3; MAPK1
  GnRH signaling pathway                      9.20×10^−4^   1.70×10^−2^   GNAQ; GNA11; MAPK3; MAPK1
  Sphingolipid metabolism                     1.47×10^−3^   2.36×10^−2^   NEU4; NEU2; NEU3
  Chagas disease (American trypanosomiasis)   1.51×10^−3^   2.36×10^−2^   GNAQ; GNA11; MAPK3; MAPK1
  T cell receptor signaling pathway           1.51×10^−3^   2.36×10^−2^   NCK1; CDK4; MAPK3; MAPK1
  Serotonergic synapse                        1.99×10^−3^   2.68×10^−2^   GNAQ; BRAF; MAPK3; MAPK1
  Endometrial cancer                          1.97×10^−3^   2.68×10^−2^   BRAF; MAPK3; MAPK1
  Cholinergic synapse                         1.93×10^−3^   2.68×10^−2^   GNAQ; GNA11; MAPK3; MAPK1
  Acute myeloid leukemia                      2.56×10^−3^   3.03×10^−2^   BRAF; MAPK3; MAPK1
  NOD-like receptor signaling pathway         2.56×10^−3^   3.03×10^−2^   CXCL1; MAPK3; MAPK1
  Neurotrophin signaling pathway              2.56×10^−3^   3.03×10^−2^   MAGED1; BRAF; MAPK3; MAPK1
  mTOR signaling pathway                      2.97×10^−3^   3.25×10^−2^   BRAF; MAPK3; MAPK1
  Viral carcinogenesis                        2.86×10^−3^   3.25×10^−2^   CDK4; HLA-E; MAPK3; MAPK1; CDKN2A
  Colorectal cancer                           3.26×10^−3^   3.44×10^−2^   BRAF; MAPK3; MAPK1
  Natural killer cell mediated cytotoxicity   3.92×10^−3^   3.87×10^−2^   BRAF; HLA-E; MAPK3; MAPK1
  Renal cell carcinoma                        3.89×10^−3^   3.87×10^−2^   BRAF; MAPK3; MAPK1
